Clinical characteristics
| . | n = 89 . | % . |
|---|---|---|
| Age, y | ||
| Median (range) | 68 (61-88) | |
| ≥70 | 35 | 39 |
| Men | 58 | 65 |
| Women | 31 | 35 |
| ECOG PS | ||
| 0 | 33 | 37 |
| 1 | 41 | 46 |
| 2 | 15 | 17 |
| B symptoms | 51 | 57 |
| Ann Arbor stage | ||
| IIB at risk∗ | 3 | 3 |
| III | 30 | 34 |
| IV | 56 | 63 |
| Bone marrow involved† | 18 | 20 |
| Hemoglobin level, median (range), g/dL | 12.4 (7-17) | |
| Albumin level, median (range), g/L | 35 (20-66) | |
| International prognostic score | ||
| 0-2 | 17 | 20 |
| 3-6 | 70 | 80 |
| Missing | 2 | |
| Histological subtype (central review) | ||
| Nodular sclerosis | 56 | 63 |
| Classic, not otherwise specified | 18 | 20 |
| Mixed cellularity | 11 | 12 |
| EBV-positive diffuse large B-cell lymphoma | 1 | 1 |
| Hodgkin lymphocyte-rich | 1 | 1 |
| Insufficient material | 1 | 1 |
| Nodular lymphocyte-predominant Hodgkin lymphoma | 1 | 1 |
| EBV association | ||
| LMP1 positivity‡ | 26 | 32 |
| EBER positivity‡ | 33 | 47 |
| Comorbidity, CIRS-G | ||
| Total score, median | 3 (0–12) | |
| Number of categories endorsed | 2 (0–14) | |
| No grade 3-4 comorbidity | 81 | 91 |
| ≥1 grade 3-4 comorbidity | 8 | 9 |
| IADL (n = 35)§ | ||
| 4 | 21 | 66 |
| ≤3 | 11 | 34 |
| Missing | 3 | |
| ADL (n = 35)§ | ||
| 6 | 25 | 81 |
| ≤5 | 6 | 19 |
| Missing | 4 | |
| MNA (n = 35)§ | ||
| Normal (>23.5) | 18 | 53 |
| At risk of malnutrition (17-23.5) | 15 | 44 |
| Malnourished (<17) | 1‖ | 3 |
| Missing | 1‖ | |
| G8 questionnaire (n = 35)§ | ||
| ≤14 | 27 | 77 |
| >14 | 8 | 23 |
| Median (range) | 11 (3-17) |
| . | n = 89 . | % . |
|---|---|---|
| Age, y | ||
| Median (range) | 68 (61-88) | |
| ≥70 | 35 | 39 |
| Men | 58 | 65 |
| Women | 31 | 35 |
| ECOG PS | ||
| 0 | 33 | 37 |
| 1 | 41 | 46 |
| 2 | 15 | 17 |
| B symptoms | 51 | 57 |
| Ann Arbor stage | ||
| IIB at risk∗ | 3 | 3 |
| III | 30 | 34 |
| IV | 56 | 63 |
| Bone marrow involved† | 18 | 20 |
| Hemoglobin level, median (range), g/dL | 12.4 (7-17) | |
| Albumin level, median (range), g/L | 35 (20-66) | |
| International prognostic score | ||
| 0-2 | 17 | 20 |
| 3-6 | 70 | 80 |
| Missing | 2 | |
| Histological subtype (central review) | ||
| Nodular sclerosis | 56 | 63 |
| Classic, not otherwise specified | 18 | 20 |
| Mixed cellularity | 11 | 12 |
| EBV-positive diffuse large B-cell lymphoma | 1 | 1 |
| Hodgkin lymphocyte-rich | 1 | 1 |
| Insufficient material | 1 | 1 |
| Nodular lymphocyte-predominant Hodgkin lymphoma | 1 | 1 |
| EBV association | ||
| LMP1 positivity‡ | 26 | 32 |
| EBER positivity‡ | 33 | 47 |
| Comorbidity, CIRS-G | ||
| Total score, median | 3 (0–12) | |
| Number of categories endorsed | 2 (0–14) | |
| No grade 3-4 comorbidity | 81 | 91 |
| ≥1 grade 3-4 comorbidity | 8 | 9 |
| IADL (n = 35)§ | ||
| 4 | 21 | 66 |
| ≤3 | 11 | 34 |
| Missing | 3 | |
| ADL (n = 35)§ | ||
| 6 | 25 | 81 |
| ≤5 | 6 | 19 |
| Missing | 4 | |
| MNA (n = 35)§ | ||
| Normal (>23.5) | 18 | 53 |
| At risk of malnutrition (17-23.5) | 15 | 44 |
| Malnourished (<17) | 1‖ | 3 |
| Missing | 1‖ | |
| G8 questionnaire (n = 35)§ | ||
| ≤14 | 27 | 77 |
| >14 | 8 | 23 |
| Median (range) | 11 (3-17) |
EBER, EBV-encoded RNA; LMP1, latent membrane protein 1.
Mediastinum/thorax ratio ≥ 0.33 or extranodal localization.
According to PET evaluation.
82 and 70 available cases for EBER and LMP1 staining, respectively.
Geriatric assessment for patients aged ≥70 years.
Without respect to major inclusion criteria.